Shin Nippon Biomedical Laboratories, Ltd.

OTCPK:SBLO.F Stock Report

Market Cap: US$428.5m

Shin Nippon Biomedical Laboratories Valuation

Is SBLO.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SBLO.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SBLO.F ($9.82) is trading above our estimate of fair value ($6.48)

Significantly Below Fair Value: SBLO.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SBLO.F?

Key metric: As SBLO.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SBLO.F. This is calculated by dividing SBLO.F's market cap by their current earnings.
What is SBLO.F's PE Ratio?
PE Ratio16.6x
EarningsJP¥3.90b
Market CapJP¥64.74b

Price to Earnings Ratio vs Peers

How does SBLO.F's PE Ratio compare to its peers?

The above table shows the PE ratio for SBLO.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average52.2x
LFCR Lifecore Biomedical
48.3x-40.1%US$274.0m
SHC Sotera Health
52.6x41.0%US$3.7b
SYNH Syneos Health
62.6x33.7%US$4.5b
STVN Stevanato Group
45x20.3%US$5.5b
SBLO.F Shin Nippon Biomedical Laboratories
16.6x9.7%US$64.7b

Price-To-Earnings vs Peers: SBLO.F is good value based on its Price-To-Earnings Ratio (16.6x) compared to the peer average (48.7x).

Price to Earnings Ratio vs Industry

How does SBLO.F's PE Ratio compare vs other companies in the US Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
REPC.F RepliCel Life Sciences
0.1xn/aUS$13.00k
No more companies available in this PE range
SBLO.F 16.6xIndustry Avg. 36.2xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SBLO.F is good value based on its Price-To-Earnings Ratio (16.6x) compared to the Global Life Sciences industry average (36.2x).

Price to Earnings Ratio vs Fair Ratio

What is SBLO.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SBLO.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SBLO.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.86

7D

3.9%

1Y

15.0%

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

7D

-1.3%

1Y

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%